^a)Latency period was defined as the interval from the first diagnosis of the primary disease to the diagnosis of t-MNs.

Abbreviations: t-AML, therapy-related acute myeloid leukemia; ABL, acute biphenotypic leukemia; DOX, doxorubicin; VP16, etoposide; MLL abn., 11q23 abnormalities; t-CMML, therapy-related chronic myelomonocytic leukemia; RMS, rhabdomyosarcoma; N/A, not available; OSA, osteosarcoma; NHL, non-Hodgkin lymphoma; ALL, acute lymphoblastic leukemia; DAU, daunorubicin; t-MDS, therapy-related myelodysplastic syndrome; SS, synovial sarcoma; NHL, non-Hodgkin lymphoma; AML, acute myeloid leukemia; IDA, idarubicin; MXT, mitoxantrone; EWS, Ewing sarcoma; BT, brain tumor; JMML, juvenile myelomonocytic leukemia; RMS, rhabdomyosarcoma; HBL, hepatoblastoma.